Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$3.34 USD
-0.08 (-2.34%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $3.35 +0.01 (0.30%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBOT 3.34 -0.08(-2.34%)
Will MBOT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBOT
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Beat the Market the Zacks Way: Ryanair, Monster Beverage, Ulta Beauty in Focus
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Other News for MBOT
Is MBOT building bearish momentum? Fell Below 20 Day Moving Average shows up after plummeting 15.56%
Microbot Medical Secures $25.2M in New Funding Round
Microbot Medical announces exercise of outstanding preferred investment options
Microbot Medical announces exercise of outstanding preferred investment options
NR7 appears for MBOT after 4.11% move